Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo
Abstract Objectives This study explored the potential of Zebularine (Zeb), a DNA methyltransferase inhibitor (DNMTi), and Valproic acid (Vpa), a histone deacetylase inhibitor (HDACi), as a combined treatment strategy for OSCC. Materials and methods OSCC cell lines, HSC4 (well-differentiated type) an...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02928-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234753861976064 |
|---|---|
| author | Shuhei Takahashi Koki Yoshida Durga Paudel Tetsuro Morikawa Osamu Uehara Fumiya Harada Dedy Ariwansa Sarita Giri Jun Sato Hiroki Nagayasu Yoshihiro Abiko |
| author_facet | Shuhei Takahashi Koki Yoshida Durga Paudel Tetsuro Morikawa Osamu Uehara Fumiya Harada Dedy Ariwansa Sarita Giri Jun Sato Hiroki Nagayasu Yoshihiro Abiko |
| author_sort | Shuhei Takahashi |
| collection | DOAJ |
| description | Abstract Objectives This study explored the potential of Zebularine (Zeb), a DNA methyltransferase inhibitor (DNMTi), and Valproic acid (Vpa), a histone deacetylase inhibitor (HDACi), as a combined treatment strategy for OSCC. Materials and methods OSCC cell lines, HSC4 (well-differentiated type) and SAS (poorly differentiated type), were cultured and treated with Zeb, Vpa, and their combinations. Cell viability, mRNA expression of P16, P21, NPY, and RASSF1 using quantitative reverse transcription polymerase chain reaction (qRT-PCR), DNA methylation using methylation-specific PCR (qMSP), and in situ HDAC activity were analyzed in vitro. In vivo, a xenograft tumor formation assay was conducted using male BALB/Slc-nu nude mice, in accordance with the Basel Declaration and The ARRIVE guidelines 2.0. Tumor samples were analyzed by qRT-PCR, and qMSP. Results In vitro experiments using the HSC4 and SAS cell lines revealed significant cytotoxic effects and upregulation of tumor suppressor genes (P16, P21, NPY, and RASSF1) after treatment with Zeb + Vpa. In vivo xenograft assay in nude mice treated with Zeb + Vpa demonstrated reduced tumor volume in HSC4 cell-transplanted tumors without significant adverse effects on the body weights of the mice, whereas no significant reduction in tumor size was observed in SAS cell-transplanted tumors compared with controls. Molecular analysis confirmed elevated gene expression levels and reduced DNA methylation percentages in the treated tumors, with a more pronounced effect in HSC4 compared to SAS. Conclusions These findings suggest that the combination of Zeb and Vpa holds promise as an effective and low-toxicity therapeutic strategy for well-differentiated type of OSCC. |
| format | Article |
| id | doaj-art-2e26aaa0c06943f7bbfe34df11aedc21 |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-2e26aaa0c06943f7bbfe34df11aedc212025-08-20T04:03:02ZengSpringerDiscover Oncology2730-60112025-07-0116111710.1007/s12672-025-02928-yEpigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivoShuhei Takahashi0Koki Yoshida1Durga Paudel2Tetsuro Morikawa3Osamu Uehara4Fumiya Harada5Dedy Ariwansa6Sarita Giri7Jun Sato8Hiroki Nagayasu9Yoshihiro Abiko10Division of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of HokkaidoDivision of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of HokkaidoAdvanced Research Promotion Center, Health Sciences University of HokkaidoDivision of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of HokkaidoDivision of Disease Control and Molecular Epidemiology, Department of Oral Growth and Development, School of Dentistry, Health Sciences University of HokkaidoDivision of Oral and Maxillofacial Surgery, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of HokkaidoDivision of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of HokkaidoAdvanced Research Promotion Center, Health Sciences University of HokkaidoDivision of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of HokkaidoDivision of Oral and Maxillofacial Surgery, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of HokkaidoDivision of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of HokkaidoAbstract Objectives This study explored the potential of Zebularine (Zeb), a DNA methyltransferase inhibitor (DNMTi), and Valproic acid (Vpa), a histone deacetylase inhibitor (HDACi), as a combined treatment strategy for OSCC. Materials and methods OSCC cell lines, HSC4 (well-differentiated type) and SAS (poorly differentiated type), were cultured and treated with Zeb, Vpa, and their combinations. Cell viability, mRNA expression of P16, P21, NPY, and RASSF1 using quantitative reverse transcription polymerase chain reaction (qRT-PCR), DNA methylation using methylation-specific PCR (qMSP), and in situ HDAC activity were analyzed in vitro. In vivo, a xenograft tumor formation assay was conducted using male BALB/Slc-nu nude mice, in accordance with the Basel Declaration and The ARRIVE guidelines 2.0. Tumor samples were analyzed by qRT-PCR, and qMSP. Results In vitro experiments using the HSC4 and SAS cell lines revealed significant cytotoxic effects and upregulation of tumor suppressor genes (P16, P21, NPY, and RASSF1) after treatment with Zeb + Vpa. In vivo xenograft assay in nude mice treated with Zeb + Vpa demonstrated reduced tumor volume in HSC4 cell-transplanted tumors without significant adverse effects on the body weights of the mice, whereas no significant reduction in tumor size was observed in SAS cell-transplanted tumors compared with controls. Molecular analysis confirmed elevated gene expression levels and reduced DNA methylation percentages in the treated tumors, with a more pronounced effect in HSC4 compared to SAS. Conclusions These findings suggest that the combination of Zeb and Vpa holds promise as an effective and low-toxicity therapeutic strategy for well-differentiated type of OSCC.https://doi.org/10.1007/s12672-025-02928-yEpigeneticsOral squamous cell carcinomaValproic acidZebularine |
| spellingShingle | Shuhei Takahashi Koki Yoshida Durga Paudel Tetsuro Morikawa Osamu Uehara Fumiya Harada Dedy Ariwansa Sarita Giri Jun Sato Hiroki Nagayasu Yoshihiro Abiko Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo Discover Oncology Epigenetics Oral squamous cell carcinoma Valproic acid Zebularine |
| title | Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo |
| title_full | Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo |
| title_fullStr | Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo |
| title_full_unstemmed | Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo |
| title_short | Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo |
| title_sort | epigenetic agents zebularine and valproic acid inhibit the growth of the oral squamous cell carcinoma cell line hsc4 in vitro and in vivo |
| topic | Epigenetics Oral squamous cell carcinoma Valproic acid Zebularine |
| url | https://doi.org/10.1007/s12672-025-02928-y |
| work_keys_str_mv | AT shuheitakahashi epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT kokiyoshida epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT durgapaudel epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT tetsuromorikawa epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT osamuuehara epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT fumiyaharada epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT dedyariwansa epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT saritagiri epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT junsato epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT hirokinagayasu epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo AT yoshihiroabiko epigeneticagentszebularineandvalproicacidinhibitthegrowthoftheoralsquamouscellcarcinomacelllinehsc4invitroandinvivo |